**TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features**

António Castanheira1,2,9, Maria João Vieira3,4,9, Mafalda Pinto3,4,9, Carolina Dias3,4, Luisa Prada3,4,5, Sofia Macedo3,4, Margarida Sá Fernandes6, Fortunato Vieira7, Paula Soares2,3,4, Alberto Mota2,8, José Manuel Lopes2,3,4,6 & Paula Boaventura2,3,4,9

Cutaneous basal cell carcinoma (cBCC) is an economic burden to health services, due to its great morbidity and increasing incidence in old people. Infiltrative cBCCs and cBCCs with micronodular pattern are considered as more aggressive. The role of p53 expression and TERTp mutation on cBCC behavior remains to be clarified. We aimed to assess TERTp mutations and p53 expression in relation to the cBCC histological subtype in a cohort of patients referred to an ENT Department of a tertiary Hospital of Northern Portugal. We performed a retrospective clinicopathological and histological review of the head and neck cBCCs followed-up at the otorhinolaryngology department of Trás-os-Montes e Alto Douro hospital (January 2007–June 2018). We assessed TERTp mutations in 142 cBCCs and p53 protein expression, through immunohistochemistry, in 157 cBCCs. We detected TERTp mutations in 43.7% of cBCCs and p53 overexpression in 60.5% of cBCCs. We spotted association of p53 overexpression and TERTp mutation with necrosis. In the infiltrative-growth pattern cBCCs, there was no significant association with the clinical and histological features evaluated, except for necrosis. In the indolent-growth cBCCs, we identified a significant association of TERTp mutation status with female sex, necrosis, multiple cBCCs, and p53 positive expression. Our results suggest that TERTp mutation may be useful to identify more aggressive features in the indolent-growth pattern cBCCs (nodular and superficial subtypes). Further studies with larger cohorts are warranted to clarify the relevance of TERTp mutation in cBCCs.

Cutaneous basal cell carcinoma (cBCC) is the most common cancer diagnosed in human populations, representing 70–80% of skin cancers1,2. Despite its very low mortality rate, it is an economic burden to health services, due to its great morbidity and increasing incidence in old people3,4. The main carcinogenic agent is ultraviolet light (UV), which is reflected by the cBCCs higher frequency in sun-exposed sites3.

cBCC is characterized by great morphological variability, both clinically and histologically4. cBCCs can be classified in three main histopathological subtypes: nodular, superficial, and infiltrative5, but cBCC with mixed histology is a common pattern1. cBCCs can present indolent or aggressive behavior5. Superficial and nodular cBCC subtypes have a more indolent behavior whereas infiltrative subtypes and BCCs with micronodular features are usually more aggressive5,6. cBCCs exhibiting infiltrative growth display a higher propensity for recurrence than well-circumscribed cBCCs so the histological subtyping is crucial for evaluating the risk of relapse4.

Several genes were associated with cBCC, including the key components of the Hedgehog pathway, PTCH1 and SMO, the TP53 tumor suppressor, and members of the RAS proto-oncogene family3. The PTCH1 gene is the most commonly mutated, involved in 90% of cBCCs4. Inactivation of the TP53 gene is also a frequent event.
associated with cBCC pathogenesis. p53 expression and its expression in actinic keratosis suggests that p53 plays a role in the early steps of carcinogenesis in skin cancers. Moreover, it has been suggested that p53 expression seems to be associated with cBCC aggressiveness, and some differences in p53 mutation frequency, types of mutation, and hot spots were seen between aggressive and nonaggressive BCCs. However, these differences do not constitute clear-cut diagnostic or prognostic indicators of tumor aggressiveness, so tumor aggressiveness may be attributable to other genetic events that occur during tumor progression.

Recent reports described non-coding mutations in the TERT promoter gene (TERTp) as a frequent event in cBCCs. Mutations in the promoter region of TERT lead to increased TERT expression and de novo telomerase activity in cancer cells, which allow cells to acquire the ability to overcome senescence and to become immortal. Telomerase up-regulation is a key, rate-limiting step in tumorigenesis as evidenced by the highly recurrent mutations in the TERT promoter. Inactivating mutations in the p53 pathway and activating mutations in the TERT promoter may be critical in enabling tumor progression. TERTp mutations have been associated with poor prognosis in several cancers including melanoma and squamous cell carcinoma, but, so far, this has not been observed in BCC. Additionally, there are no reports describing an association of the genetic profile with specific histopathological cBCC subtypes, namely the more aggressive infiltrative subtype.

Taking this into account, we aimed to assess p53 expression and TERTp mutation status in cBCC, and associate them with histological subtype and clinicopathological features, in a cohort of cBCC patients.

Material and methods

Cases studied. Selection criteria for inclusion in this retrospective series were all cases of histologically confirmed cutaneous BCCs (cBCCs) located in head and neck, managed at the ENT Department of the Centro Hospitalar de Trás-os-Montes e Alto Douro (CHTMAD), from January 2007 to June 2018. Exclusion criteria included age < 18 year-old, genetic diseases or syndromes predisposing to cBCC, genetic disorders associated with other neoplasms, diffuse dermatosis, and biopsies from recurrence or persistence of a previously diagnosed cBCC. Applying these criteria, 151 patients were included and signed an informed consent after proper information about the goal and scope of the study. Data from these patients were gathered in a personal interview questionnaire, using medical records (Scinico database and Clinical Process), and pathological records from the Pathology Department at CHTMAD. The Ethical Committee and the Administrative Council of CHTMAD approved the study in 16/10/2012. All the methods were performed in accordance with relevant guidelines and regulations.

Patient melanin content in the forehead and inner arm was measured with a DermaSpectrometer (Cortex Technology, Hadsund, Denmark) as described by Shriver and Parra. Sun-exposure was assessed according to the patient's profession and lifestyle—high exposure was considered for patients who had professions with many hours of sun exposure such as farmers and construction workers.

Patients with previous incomplete or inappropriate histological records, missing information, or histological samples in inappropriate conditions were excluded (n = 55), so we ended up with 96 patients. Of these 96 patients, 36 had more than one BCC. The final series comprised 160 cBCCs from 96 patients.

cBCC histopathological features were reviewed by a pathologist (MSF), under the supervision of a senior pathologist/dermatopathologist (JML), to assess detailed histological data for each tumor. The morphological classification of cBCCs was performed according to Rippey and included the following growth patterns: nodular, infiltrative (including morpheic), superficial or mixed (including a combination of at least two of the aforementioned patterns). The cBCCs were further classified as cBCCs with an infiltrative-type growth pattern, considered as more aggressive, which included BCCs with infiltrative, morpheic or micronodular component, and BCCs with an indolent-type growth pattern, considered as less aggressive, which included the nodular and superficial subtypes.

p53 immunohistochemistry. p53 protein expression in cBCCs was evaluated through immunohistochemistry. Briefly, deparaffinized and rehydrated sections were subjected to a 45' steamer treatment in 10 mM sodium citrate buffer, pH 6.0, for antigen retrieval. Ultravision hydrogen peroxide block (Ref TA-060-H202Q, Thermo Scientific) and protein block (Ref TA-125-PBQ, Thermo Scientific) were used to block endogenous peroxidase activity. Briefly, deparaffinized and rehydrated sections were subjected to a 45' steamer treatment in 10 mM sodium citrate buffer, pH 6.0, for antigen retrieval. Ultravision hydrogen peroxide block (Ref TA-060-H202Q, Thermo Scientific) and protein block (Ref TA-125-PBQ, Thermo Scientific) were used to block endogenous peroxidase activity. Subsequently, we used the monoclonal antibody anti-p53 (NCL-P53, Leica), diluted 1:550 (Ref TA-125-ADQ, Thermo Scientific), for 60' at room temperature. The monoclonal antibody (clone DO-7) recognizes both wild type and mutant forms of human p53 protein under denaturing and non-denaturing conditions. After this step, sections were processed for the detection of positive immunohistochemical reaction with HRP polymer quantum (Ref TL-060-QPH, Thermo Scientific) for 10', and further reaction with 3% diaminobenzidine chromogen (DAB, Ref K3468, Dako), for 3'. Finally, sections were counterstained with Mayer's hematoxylin, cleared and mounted.

For the p53 staining evaluation, the slides were digitalized using the scanner D-sight FLUO (A-MENARINI diagnostics, UK) and its automatized analysis program with a previously developed p53 algorithm. Approximately 2000 cells were counted in each cBCC.

The scoring of tumors was done as follows: staining < 10% of tumor cells were considered as negative, and staining ≥ 10% was considered as positive.

Molecular analysis: TERTp mutations. TERTp mutation analysis was performed as previously described. Briefly, cBCCs areas were manually dissected from 10-µm whole sections of paraffin-embedded material. DNA extraction was performed using with GRISP kit (GRISP, Portugal) according to the manufacturer instructions. After the last centrifugation, DNA was quantified with the Nanodrop (ND-1000, Thermo Fisher Scientific, Lithuania). Mutation analysis was performed with Sanger sequencing. Briefly, genomic DNA
(25–100 ng) was amplified by polymerase chain reaction (PCR) with the kit from Bioline (MyTaq HS Mix 2X, USA), using the following set of primers: forward TERTF, CAGCGGTGCTGAAAATG, and reverse TERTR, GTCTGGCCCTTCACCTT. The following cycling conditions were used: 35 s at 94 °C; 40 s at 62 °C and 45 s at 72 °C for 40 cycles. Products were enzymatically purified with Exonuclease I and Shrimp Alkaline Phosphatase and sequenced in an ABI Prism 3130 xl Automatic sequencer (Perkin-Elmer, Foster City, CA) using the BigDye v3.1 Sequencing Kit (Applied Biosystems, Washington). Cases with mutations were confirmed by an independent PCR amplification. Additionally, randomly selected cases were confirmed using real-time PCR amplification curve analysis25. Positive and negative mutation control samples were included in each run to ensure the assay's validity.

Statistical analysis. Statistical analysis was performed using the statistical package for social sciences software (IBM SPSS Statistics 23). Proportions were compared using the X^2 test or Fisher's exact test when appropriate (Yates correction in case of multiple entries); the significance of differences between means was assessed with Student's unpaired t-test. A p value < 0.05 was considered statistically significant with a 95% confidence interval.

Ethics approval. The Ethical Committee and the Administrative Council of CHTMAD approved the study in 16/10/2012.

Consent to participate. Patients signed an informed consent after proper information about the goal and scope of the study.

Results

p53 immunostaining. p53 positive staining (≥ 10% of the stained tumor cells) was observed in the nucleus of 95 out of 157 cBCCs (60.5%; in three cases the evaluation was not possible due to unspecific staining) (Fig. 1). None of the cases displayed either absence of expression or cytoplasm expression of p53 in the tumor cells. No significant differences were observed concerning age at diagnosis, sex, skin melanin content in inner arm, solar exposure, and presence of multiple cBCCs, between p53 positive and p53 negative cBCCs (Table 1).

Concerning cBCCs histopathological features (tumor thickness, tumor dimension, location, histological subtype, invasion level, ulceration, associated actinic keratosis, necrosis, tumor pigmentation, elastosis, and growth pattern), no significant differences were found according to p53 positive expression except for necrosis, which was a more frequent finding in the p53 positive cBCCs (25.5%) comparing with the negative ones (11.7%) (p = 0.036) (Table 2).

Additionally, we repeated the same analysis separately for cBCC with infiltrative-type growth pattern vs indolent-type growth pattern, as this classification reflects BCC aggressiveness. In cBCCs with indolent-type growth pattern, we observed a significant association of p53 expression with TERTp mutation, which will be described in the next section. We also observed an association of necrosis with p53 expression in this subgroup, which had been already observed when analyzing all the cBCCs together. A higher frequency of necrosis was observed in cBCCs with positive p53 expression (11/34, 32.4%) comparing with p53 negative cBCCs (1/22, 4.5%) (p = 0.018). No significant associations were found in the infiltrative-type growth pattern group.

TERTp mutations. We attained information on TERTp mutation status in 142 cBCCs of the 160 cBCCs evaluated (88.8%); in 18 cases, we could not obtain enough DNA or DNA quality to ensure a proper amplification. In these 142 cases we did not achieve p53 evaluation in threes cases, meaning we had 139 cases with evaluation of both, TERTp mutations and p53 expression. In the142 cBCCs, 62 were TERTp mutated
Table 1. Clinicopathological features and p53 expression in cBCCs.

| Clinicopathological features                  | Total cBCC | p53 negative (<10%) | p53 positive (≥10%) | p value |
|-----------------------------------------------|------------|----------------------|---------------------|---------|
| Age at diagnosis (mean ± SD) (n = 157)        |            |                      |                     |         |
| Sex [n (%)] [n (157)]                         |            |                      |                     |         |
| Male                                          | 82 (52.2)  | 35 (56.5)            | 47 (49.5)           | 0.467   |
| Female                                        | 75 (48.8)  | 27 (43.5)            | 48 (50.5)           |         |
| Skin melanin content (inner arm) (mean ± SD) (n = 124) |            |                      |                     |         |
| Low                                           | 34 (25.4)  | 13 (25.5)            | 21 (25.3)           | 0.981   |
| High                                          | 100 (74.6) | 38 (74.5)            | 62 (74.7)           |         |
| Location [n (%)] (n = 157)                    |            |                      |                     |         |
| Nose                                          | 39 (24.9)  | 14 (22.6)            | 25 (26.3)           | 0.997   |
| Face                                          | 47 (29.9)  | 19 (30.6)            | 28 (29.5)           |         |
| Eyelid                                        | 31 (19.8)  | 14 (22.6)            | 17 (17.9)           |         |
| Preauricular / auricular region                | 27 (17.2)  | 9 (14.5)             | 18 (18.9)           |         |
| Scalp                                         | 1 (0.6)    | 1 (1.6)              | 0 (0)               |         |
| Lip                                           | 6 (3.8)    | 3 (4.8)              | 3 (3.2)             |         |
| Tumor dimension (mean ± SD) (n = 154)         | 13.2 ± 9.8 | 13.3 ± 8.1           | 13.2 ± 10.8         | 0.987   |
| Focality [n (%)] (n = 157)                    |            |                      |                     |         |
| Single                                        | 61 (38.9)  | 24 (38.7)            | 37 (38.9)           | 0.976   |
| Multiple                                      | 96 (61.1)  | 38 (61.3)            | 58 (61.1)           |         |

Table 2. cBCCs histopathological features and p53 expression. Bold - significant difference (p-value < 0.05).

| Histopathological features                  | Total cBCC | p53 negative (<10%) | p53 positive (≥10%) | p value |
|---------------------------------------------|------------|----------------------|---------------------|---------|
| Tumor thickness (mean ± SD) (n = 151)       | 2.4 ± 1.7  | 2.4 ± 1.8            | 2.3 ± 1.5           | 0.713   |
| Histological subtype [n (%)] (n = 157)      |            |                      |                     |         |
| Nodular                                     | 56 (35.7)  | 24 (38.7)            | 32 (33.7)           |         |
| Infiltrative                                 | 51 (32.5)  | 20 (32.3)            | 31 (32.6)           | 0.444   |
| Mixed                                       | 44 (28.0)  | 16 (25.8)            | 28 (29.5)           |         |
| Superficial                                 | 6 (3.8)    | 2 (3.2)              | 4 (4.2)             |         |
| Invasion level [n (%)] (n = 152)            |            |                      |                     |         |
| Papillary dermis                            | 8 (5.2)    | 2 (1.3)              | 6 (6.5)             | 0.547   |
| Reticular dermis                            | 84 (55.3)  | 30 (50.0)            | 54 (58.7)           |         |
| Subcutaneous                                | 58 (38.2)  | 26 (43.3)            | 32 (34.8)           |         |
| Intramuscular                               | 2 (1.3)    | 2 (3.3)              | 0 (0)               |         |
| Tumor features [n (%)]                      |            |                      |                     |         |
| Ulceration (n = 153)                        | 95 (62.1)  | 34 (58.6)            | 61 (64.2)           | 0.489   |
| Actinic keratosis (n = 152)                 | 14 (9.2)   | 4 (6.8)              | 8 (8.6)             | 0.767   |
| Necrosis (n = 154)                          | 31 (20.1)  | 7 (11.7)             | 24 (25.5)           | 0.036   |
| Pigmentation (n = 154)                      | 14 (9.1)   | 8 (13.3)             | 6 (6.4)             | 0.143   |
| Elastosis (n = 153)                         | 14 (9.2)   | 6 (10.0)             | 8 (8.6)             | 0.77    |
| Lymphocytic infiltrate [n (%)] (n = 156)     |            |                      |                     |         |
| Absent/Rare                                  | 82 (52.6)  | 34 (55.7)            | 48 (50.5)           | 0.525   |
| Moderate/Intense                            | 74 (47.4)  | 27 (44.3)            | 47 (49.5)           |         |
| Lymphovascular invasion [n (%)] (n = 150)    |            |                      |                     |         |
| Not identified                               | 145 (96.7) | 56 (94.9)            | 89 (97.8)           | 0.807   |
| Present                                     | 5 (3.3)    | 3 (5.1)              | 2 (2.2)             |         |
| Perineural invasion [n (%)] (n = 152)        |            |                      |                     |         |
| Not identified                               | 142 (94.0) | 56 (93.3)            | 86 (94.5)           | 0.967   |
| Present                                     | 9 (6.0)    | 4 (6.7)              | 5 (5.5)             |         |
| Growth pattern [n (%)] (n = 157)             |            |                      |                     |         |
| Indolent-type                                | 56 (35.7)  | 22 (35.5)            | 34 (35.8)           | 0.969   |
| Aggressive-type                              | 101 (64.3) | 40 (64.5)            | 61 (64.2)           |         |
The most frequent mutation was the $-146: \text{G} > \text{A}$ mutation, which occurred in 48 of 62 cases (77.4%). The $-124: \text{G} > \text{A}$ occurred in 13 out of 62 cases (21.0%) (Fig. 2). In one cBCC, we observed the tandem mutation $-124/125: \text{GG} > \text{AA}$ (Fig. 2), and in another cBCC the $-124: \text{G} > \text{A}$ and $-146: \text{G} > \text{A}$ simultaneous mutations were observed (1.6%).

No significant differences were observed concerning age at diagnosis, sex, skin melanin content in the forearm, solar exposure, and presence of multiple cBCCs, between $\text{TERTp}$ mutated and $\text{TERTp}$ wild type (wt) cBCCs (Table 3).

Concerning cBCCs histopathological features (tumor thickness, tumor dimension, location, histological subtype, invasion level, ulceration, associated actinic keratosis, skin pigmentation, elastosis, and growth pattern) no significant differences were found according to the $\text{TERTp}$ mutation status (Table 4), except for a significant association with necrosis, which was more frequent in $\text{TERTp}$ mutated cBCCs (33.9%), compared with the $\text{TERTp}$ wt cBCCs (10.3%) ($p = 0.001$). No association was found between p53 expression and $\text{TERTp}$ mutation status in this cohort of cBCCs.

The significant association with necrosis, observed when we considered the whole cBCCs analyzed, persisted when the groups were split according to the growth pattern. In cBCCs with infiltrative-type growth pattern, necrosis was present in 12 out of 43 $\text{TERTp}$ mutated cBCCs (27.9%), compared with 5 out of 46 $\text{TERTp}$ wt cBCCs (10.9%) ($p = 0.041$). No other significant associations were found in the infiltrative-type growth pattern group. In cBCCs with indolent-type growth pattern, significant associations were observed for $\text{TERTp}$ mutation status and female sex, multiple cBCC, and p53 positive expression (Table 5).

Finally, we compared p53 positive and $\text{TERTp}$ mutated cases, with p53 negative and $\text{TERTp}$ wild type cases (data not shown). The only significant difference found was the frequency of necrosis. cBCCs p53 positive and $\text{TERTp}$ mutated had more frequently necrosis (17/37, 45.9%) when compared with cBCCs p53 negative and $\text{TERTp}$ wild type (4/31, 12.9%) ($p = 0.003$).

**Discussion**

In the present study, $\text{TERTp}$ mutations and p53 expression were evaluated in cBCCs from patients referred to an ENT Hospital Department. We observed that 32% of the cBCCs were of the infiltrative subtype, which is considered as more aggressive due to its higher risk of subclinical tumor extension. In most series, lower frequencies of infiltrative cBCC were reported, ranging from 4.2 to 8.7%. Leibovitch et al. reported a higher frequency, 28.3%, which they ascribed to a referral bias for Micrographic Mohs Surgery (MMS). The second most frequent subtype detected in the present study was the mixed cBCC subtype. Again, this may be related to a more aggressive pattern, since mixed type cBCCs have been reported as more frequently composed of aggressive subtypes.

The cBCC location distribution of our series, with the face and nose as the main locations, is in line with what was been reported in other studies. A relevant proportion of the cBCCs invaded the deep skin layers (reticular dermis and subcutaneous layer) when compared with other studies. Indeed, Bandeira et al. did not report invasion deeper than the reticular dermis, but Betti et al. reported subcutaneous fat invasion in
### Table 3. Clinicopathological features in cBCCs and TERTp mutation status.

| Clinicopathological features                        | Total cBCCs (n = 142) | TERTwt (n = 80) | TERTmut (n = 62) | p value |
|----------------------------------------------------|------------------------|----------------|----------------|---------|
| Age at diagnosis (mean ± SD) (n = 142)             | 72.4 ± 11.2            | 72.4 ± 11.1    | 72.7 ± 11.3    | 0.887   |
| Sex [n (%)] (n = 142)                              |                        |                |                |         |
| Male                                               | 78 (54.9)              | 46 (57.5)      | 32 (51.6)      | 0.484   |
| Female                                             | 64 (45.1)              | 34 (42.5)      | 30 (48.4)      |         |
| Skin melanin content (inner arm) (mean ± SD) (n = 114) | 28.3 ± 3.3             | 28.3 ± 3.7     | 28.2 ± 2.8     | 0.924   |
| Sun exposure (mean ± SD) (n = 121)                 |                        |                |                |         |
| Low                                                | 30 (24.8)              | 17 (25.4)      | 13 (24.1)      | 0.869   |
| High                                               | 91 (75.2)              | 50 (74.6)      | 41 (75.9)      |         |
| Location [n (%)] (n = 142)                         |                        |                |                | 0.876   |
| Nose                                               | 31 (21.8)              | 17 (21.3)      | 14 (22.6)      |         |
| Face                                               | 43 (30.3)              | 23 (28.7)      | 20 (32.3)      |         |
| Eyelid                                             | 30 (21.1)              | 21 (26.3)      | 9 (14.5)       |         |
| Preauricular/Auricular region                       | 26 (18.3)              | 14 (17.5)      | 12 (19.4)      |         |
| Scalp                                              | 1 (0.7)                | 0 (0)          | 1 (1.6)        |         |
| Lip                                                | 5 (3.5)                | 3 (3.8)        | 2 (3.2)        |         |
| Other                                               | 6 (4.2)                | 2 (2.5)        | 4 (6.5)        |         |
| Tumor dimension (mean ± SD) (n = 142)              | 13.6 ± 10.1            | 14.0 ± 11.7    | 13.1 ± 7.7     | 0.612   |
| Other                                              |                        |                |                |         |
| Focality [n (%)] (n = 142)                         |                        |                |                | 0.232   |
| Single                                             | 56 (39.4)              | 35 (43.8)      | 21 (33.9)      |         |
| Multiple                                           | 86 (60.6)              | 45 (56.2)      | 41 (66.1)      |         |

### Table 4. cBCCs histopathological features and TERTp mutation status. Bold - significant difference (p-value < 0.05).

| Histopathological features                        | Total cBCCs (n = 142) | TERTwt (n = 80) | TERTmut (n = 62) | p value |
|----------------------------------------------------|------------------------|----------------|----------------|---------|
| Tumor thickness (mean ± SD) (n = 136)              | 2.44 ± 1.72            | 2.21 ± 1.57    | 2.73 ± 1.87    | 0.081   |
| Histological subtype (n = 142)                     |                        |                |                |         |
| Nodular                                            | 52 (36.6)              | 25 (31.3)      | 27 (43.5)      |         |
| Infiltrative                                       | 45 (31.7)              | 30 (37.5)      | 15 (24.2)      | 0.095   |
| Mixed                                              | 39 (27.5)              | 19 (23.8)      | 20 (32.3)      |         |
| Superficial                                        | 6 (4.2)                | 6 (7.5)        | 0 (0)          |         |
| Invasion level                                     |                        |                |                |         |
| Papillary dermis                                   | 7 (5.1)                | 7 (9.2)        | 0 (0)          | 0.178   |
| Reticular dermis                                   | 76 (55.1)              | 42 (55.3)      | 34 (54.8)      |         |
| Subcutaneous                                       | 53 (38.4)              | 26 (34.2)      | 27 (43.5)      |         |
| Intramuscular                                      | 2 (1.4)                | 1 (1.3)        | 1 (1.6)        |         |
| Tumor features                                     |                        |                |                |         |
| Ulceration (n = 139)                               | 50 (36.0)              | 27 (34.6)      | 23 (37.7)      | 0.706   |
| Actinic keratosis (n = 139)                        | 11 (7.9)               | 7 (9.0)        | 4 (6.6)        | 0.755   |
| Necrosis (n = 140)                                 | 29 (20.7)              | 8 (10.3)       | 21 (33.9)      | 0.001   |
| Pigmentation (n = 140)                             | 13 (9.3)               | 9 (11.5)       | 4 (6.5)        | 0.303   |
| Elastosis (n = 139)                                | 13 (9.4)               | 9 (11.7)       | 4 (6.5)        | 0.292   |
| Lymphocytic infiltrate (n = 142)                   |                        |                |                |         |
| Absent/Rare                                        | 76 (53.5)              | 39 (48.8)      | 37 (59.7)      | 0.195   |
| Moderate/Intense                                   | 66 (46.5)              | 41 (51.2)      | 25 (40.3)      |         |
| Lymphovascular invasion (n = 136)                  |                        |                |                |         |
| Not identified                                     | 132 (97.1)             | 71 (94.7)      | 61 (100)       | 0.187   |
| Present                                            | 4 (2.9)                | 4 (5.3)        | 0 (0)          |         |
| Perineural invasion (n = 137)                      |                        |                |                |         |
| Not identified                                     | 128 (93.4)             | 70 (92.1)      | 58 (95.1)      | 0.725   |
| Present                                            | 9 (6.6)                | 6 (7.9)        | 3 (4.9)        |         |
| Growth pattern (n = 142)                           |                        |                |                |         |
| Indolent-type                                      | 51 (35.9)              | 32 (40.0)      | 19 (30.6)      | 0.249   |
| Infiltrative-type                                  | 91 (64.1)              | 48 (60.0)      | 43 (69.4)      |         |
Multiple cBCCs are a sign of aggressiveness as they increase the risk of relapse. In previous studies from our group, we found a frequency ranging from 30.0 to 38.1% but similar to the values observed by Haghighi et al.; both authors used the ≥ 10% cut-off to define cBCCs. The −146:G > A mutation is more common than −124:G > A mutation. One cBCC harbored concurrently the −146:G > A mutation with necrosis, which also occurred for p53 overexpression. Information about necrosis as a prognosis factor in BCC is scarce. Welsch et al. reported a 55.6% frequency of the −146:G > A mutation. Skin cancers seem to be the only cancers where −146:G > A, which occurred in 79% of the cases. In a previous study from our group, a similar frequency of the −146:G > A mutation was detected in a cohort of cBCCs occurring after irradiation in childhood for tinea capitis (75%), but in the sporadic context (non-irradiated control group) only 25% of the mutated cBCCs harbored this mutation. Other studies, such as the one from Griewank et al. reported a 55.6% frequency of the −146:G > A mutation. Skin cancers seem to be the only cancers where the −146:G > A mutation is more common than −124:G > A mutation. One cBCC harbored concurrently the −124:G > A and the −146:G > A mutations, and other harbored the tandem mutation at position −124/−125, rare events previously reported by our group.

Table 5. Features significantly associated with TERTp mutation status in indolent-type growth pattern cBCCs. Bold - significant difference (p-value < 0.05).

| Features | Total (n = 51) | wt (n = 32) | TERTp (n = 19) | p value |
|----------|---------------|-------------|----------------|---------|
| **Sex [n (%)]** | | | | |
| Male | 23 (45.1) | 18 (56.3) | 5 (26.3) | 0.038 |
| Female | 28 (54.9) | 14 (43.7) | 14 (73.7) | |
| **Focality [n (%)]** | | | | |
| Single | 20 (39.2) | 16 (50.0) | 4 (21.1) | 0.041 |
| Multiple | 31 (60.8) | 16 (50.0) | 15 (78.9) | |
| **p53** | | | | |
| p53 negative (<10%) | 16 (38.0) | 3 (15.8) | 13 (46.4) | 0.020 |
| p53 positive (≥10%) | 31 (62.0) | 16 (84.2) | 15 (53.6) | |
| **Necrosis** | | | | |
| Absent | 38 (74.5) | 29 (90.6) | 10 (52.6) | 0.005 |
| Present | 23 (25.5) | 3 (9.4) | 9 (47.4) | |

It has been reported that p53 overexpression is significantly higher in aggressive cBCCs compared with the non-aggressive ones. Our data do not corroborate this finding since cBCCs with indolent-type or infiltrative–type growth pattern displayed an equivalent frequency of p53 overexpression. Furthermore, other authors reported that overexpression of p53 does not always reflect the degree of malignancy in cutaneous neoplasms.

Regarding TERTp mutations, 42% of the cBCCs were mutated, a lower frequency than the previously reported (51.7-82%). The most frequent mutation was the −146:G > A, which occurred in 79% of the cases. In a previous study from our group, a similar frequency of the −146:G > A mutation was detected in a cohort of cBCCs occurring after irradiation in childhood for tinea capitis (75%), but in the sporadic context (non-irradiated control group) only 25% of the mutated cBCCs harbored this mutation. Other studies, such as the one from Griewank et al. reported a 55.6% frequency of the −146:G > A mutation. Skin cancers seem to be the only cancers where the −146:G > A mutation is more common than −124:G > A mutation. One cBCC harbored concurrently the −124:G > A and the −146:G > A mutations, and other harbored the tandem mutation at position −124/−125, rare events previously reported by our group.

Griewank et al. found no statistically significant associations of TERTp mutation with cBCC clinical and histopathologic features, nor did our group in previous studies. Noteworthy, in the present study, we observed an association of TERTp mutation with necrosis, which also occurred for p53 overexpression.

TERTp mutation has not been reported as a prognostic factor in cBCCs, at variance with other skin cancers, such as squamous cell carcinoma and melanoma, in which TERTp mutations were associated with an ominous outcome. Contrarily, in the bladder cancer model, the −146:G > A was an independent predictor of nonrecurrence after BCG therapy in the BCG-NMI tumors.

We have compared p53 positive and TERTp mutated cases, with p53 negative and TERTp wild type cases (data not shown), observing that cases with concomitantly p53 positive and TERTp mutated did not present more aggressive features, as it could be anticipated. Again, the only significant association found was with necrosis.
mutations seem to play an important role in the dedifferentiation process in these tumours. In thyroid cancer, the concomitant presence of TERTp and TP53 mutations may be useful for the identification of more aggressive tumours. In the hepatocellular carcinoma model, Shulze et al. found that TERTp mutations were early event in tumour progression whereas TP53 alterations appeared at more advanced stages in aggressive tumors. In urothelial cancer, Wu et al. have observed a significant co-occurrence of mutations between the TERT promoter and the tumor protein 51/retinoblastoma1 (TP53/RB1) signaling pathway, indicating that they may cooperatively contribute to the genesis and progression of bladder cancer. Overall, these data show that the concomitant presence of TERTp and p53 mutations is these tumours is associated with a more aggressive pattern. Although this kind of associations were not described in cBCC, p53 positive expression, and presence of multiple cBCCs, are features independently related to cBCCs aggressiveness.

This study has limitations which do not allow establishing TERTp as a new prognostic marker for cBCCs. First, we would need to have a validation cohort, which was not possible in the present study. Second, additional experiments would be needed to establish the association between p53 over expression and TERTp mutation.

In conclusion, it seems that TERTp mutation may potentially be useful to discriminate more aggressive indolent-type growth pattern cBCCs, but further studies with larger cohorts are warranted to clarify the relevance of TERTp mutations in cBCCs.

**Date availability**

Full date will be made available upon request to the corresponding author.

Received: 7 September 2020; Accepted: 4 May 2021
Published online: 17 May 2021

**References**

1. Correia de Sá, T. R., Silva, R. & Lopes, J. M. Basal cell carcinoma of the skin (part 1): epidemiology, pathology and genetic syndromes. *Future Oncol.* 11(22), 3011–3021 (2015).
2. Peris, K. et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. *Eur. J. Cancer* 118, 10–34 (2019).
3. Pellegrini, C. et al. Understanding the molecular genetics of basal cell carcinoma. *Int. J. Mol. Sci.* 18(11), 2485 (2017).
4. Lang, B. M. et al. S2k guidelines for cutaneous basal cell carcinoma-part 1: epidemiology, genetics and diagnosis. *JDDG* 17(1), 94–103 (2019).
5. Verkouteren, J. Basal cell carcinoma: biology, morphology and clinical implications. *Mod. Pathol.* 19(2), S127–S147 (2006).
6. Yalçın, U. K. & Seçkin, S. The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases. *Turk Patoloji Derg.* 28(2), 119–127 (2012).
7. Crowson, A. N. Basal cell carcinoma: biology, morphology and clinical implications. *Mod. Pathol.* 19(2), S127–S147 (2006).
8. Pyne, J., Sapkota, D. & Wong, J. C. Aggressive basal cell carcinoma: dermatoscopy vascular features as clues to the diagnosis. *Dermatol. Pract. Concept.* 2(3), 0203a02 (2012).
9. Enache, A. O. et al. Immunohistoexpression of p53 and COX-2 in basal cell carcinoma. *Rom. J. Morphol. Embryol.* 59(4), 1115–1120 (2018).
10. Ansarin, H., Daliri, M. & Soltani-Arabshahi, R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. *Eur. J. Dermatol.* 16(5), 543–547 (2006).
11. Ausepukkate, S., Boonyaphibhat, P. & Thongsukai, P. p53 expression related to the aggressive infiltrative histopathological feature of basal cell carcinoma. *Histopathology* 40(6), 568–573 (2002).
12. Koseoglu, R. D. et al. Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas. *J. Cutan. Pathol.* 36(9), 958–965 (2009).
13. Boshakov, S. et al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. *Clin. Cancer Res.* 9(1), 228–234 (2003).
14. Scott, G. A., Laughlin, T. S. & Rothberg, P. G. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. *Mod. Pathol.* 27(4), 516 (2014).
15. Populo, H. et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. *J. Invest. Dermatol.* 134(8), 2251–2257 (2014).
16. Grewan, K. G. et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. *PloS ONE* 8(11), e83054 (2013).
17. Lombardo, D. et al. Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy. *Oncol. Lett.* 19(3), 2368–2374 (2020).
18. Roske, C. M. & Artandi, S. E. Control of cellular aging, tissue function, and cancer by p53 downstream of telomeres. *Cold Spring Harb. Perspect. Med.* 7(5), 1–16 (2017).
19. Campos, M. A. et al. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. *J. Am. Acad. Dermatol.* 80(3), 660–669 (2019).
20. Hafezi, F. & Perez Bercoff, D. The solo play of TERT promoter mutations. *Cells* 9(3), 749 (2020).
21. Shriver, M. D. & Parra, E. J. Comparison of narrow-band reflectance spectroscopy and tristimulus colorimetry for measurements of skin and hair color in persons of different biological ancestry. *Ann J Phys Anthropol Off Publ Am Assoc Phys Anthropol* 112(1), 17–27 (2000).
22. Rippey, J. Why classify basal cell carcinomas?. *Histopathology* 32(5), 393–398 (1998).
23. Stamatelli, A. et al. B-Raf mutations, microsatellite instability and p53 protein expression in sporadic basal cell carcinomas. *Pathol Oncol Res* 17(3), 633–637 (2011).
24. Haighighi, R. G. F. Immunohistochemistry evaluation of p53 protein in basal cell carcinoma. *Iran. J. Allergy Asthma Immunol.* 4(4), 167–171 (2005).
25. Batista, R. et al. Validation of a novel, sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer in a comprehensive multicenter study. *Front. Genet.* 10, 1237 (2019).
26. Newlands, C. et al. Non-melanoma skin cancer: United Kingdom national multidisciplinary guidelines. *J. Laryngol. Otol.* 130(S2), S125–S132 (2016).
27. Bartos, V. & Kullova, M. Basal cell carcinoma of the skin with mixed histomorphology: a comparative study. *Ceskoslov. Patol.* 52(4), 222–226 (2016).
28. Mantese, S. A. O. et al. Carcinoma basocelular-Análise de 300 casos observados em Uberlândia-MG Basal cell Carcinoma-Analysis of 300 cases observed in Uberlândia-MG, Brazil. *An. Bras. Dermatol.* 18(2), 136–142 (2006).
29. Scrivener, Y., Grosshans, E. & Cribier, B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br. J. Dermatol. 147(1), 41–47 (2002).

30. Demirseren, D. D. Histological review of the cases. All authors reviewed the manuscript.

31. Sexton, M., Jones, D. B. & Maloney, M. E. Histologic pattern analysis of basal cell carcinoma: study of a series of 1039 consecutive neoplasms. J. Am. Acad. Dermatol. 23(6), 1118–1126 (1990).

32. Boaventura, P. et al. Mitochondrial D310 D-loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. J. Dermatol. Sci. 73(1), 31–39 (2014).

33. Leibovitch, I. et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J. Am. Acad. Dermatol. 53(3), 452–457 (2005).

34. Ghanadan, A. et al. Characteristics of mixed type basal cell carcinoma in comparison to other BCC subtypes. Indian J. Dermatol. 59(1), 56–59 (2014).

35. Bourlioud, E. et al. Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre. Eur. J. Dermatol. 29(5), 490–499 (2019).

36. Bandeira, A. M. et al. Basal cell carcinomas: anatomopathological and clinical study of 704 tumors. An. Bras. Dermatol. 78(1), 23–34 (2003).

37. Betti, R. et al. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J. Dermatol. 37(7), 611–616 (2010).

38. Betti, R. et al. Solitary fibrous tumor: a case series identifying pathological adverse factors-implications for risk stratification and classification. Virchows Arch. 476(4), 597–607 (2020).

39. Ying, Y. & Padanilam, B. J. Regulation of necrotic cell death: p53, PARP1 and cyclophilin D-overlapping pathways of regulated necrosis. Cell. Mol. Life Sci. 78(11), 2309–2324 (2016).

40. Onodera, H., Nakamura, S. & Sugai, T. Cell proliferation and p53 protein expressions in cutaneous epithelial neoplasms. Am. J. Dermatopathol. 18(6), 580–588 (1996).

41. Campos, M. A. C. et al. Trends of cutaneous squamous cell carcinoma in the hospital of Gaia (2004–2013). J. Portug. Soc. Dermatol. Venereol. 76(3), 279–286 (2018).

42. Batista, R. et al. TERT promoter mutation as a potential predictive biomarker in BCG-treated bladder cancer patients. Int. J. Mol. Sci. 21(3), 947 (2020).

43. Machado, I. et al. Solitary fibrous tumor: a case series identifying pathological adverse factors-implications for risk stratification and classification. Virchows Arch. 476(4), 597–607 (2020).

44. Akaie, K. et al. Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. Hum. Pathol. 46(3), 347–356 (2015).

45. Marotta, V. et al. Application of molecular biology of differentiated thyroid cancer for clinical prognostication. Endocr. Relat. Cancer 23(11), R499–R515 (2016).

46. Romei, C. & Elisei, R. A narrative review of genetic alterations in primary thyroid epithelial cancer. Int. J. Mol. Sci. 22(4), 1726–1741 (2021).

47. Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47(5), 505–511 (2015).

48. Wu, S. et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur. Urol. 65(2), 274–277 (2014).

49. MercuŢ, R. et al. Expression of p53, D2–40 and α-smooth muscle actin in different histological subtypes of facial basal cell carcinoma. Rom. J. Morphol. Embryol. 55(2), 263–272 (2014).

Author contributions
A.C., A.M., J.M.L., P.S. conceived the study, A.C., M.J.V. and P.B.; wrote the main manuscript text, A.C. and P.B. did the statistical analysis and prepared the tables, A.C. and M.J.V prepared Fig. 1, C.D., M.J.V. and M.P. did the genetic analysis, L.P., M.J.V. and S.M. did the immunocytochemistry, A.C., F.V., J.M.L. and M.S.F. did the histological review of the cases. All authors reviewed the manuscript.

Funding
This study was supported by FCT, the Portuguese Foundation for Science and Technology through a Ph.D Grant to SM (SFRH/BD/137802/2018). This work was financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT-Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274). Additional funding by the European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalization—COMPETE2020, and Portuguese national funds via FCT, under project POCI-01-0145-FEDER-016390: CANCEL STEM and from the FCT, under the project POCI-01-0145-FEDER-031438: The other faces of telomerase: Looking beyond tumour immortalization (PDTC/MED-ONC/31438/2017).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to P.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
